Search for a trial

Mental Health Promotion and Intervention in Occupational Settings: A Pilot Study

The project aims to improve mental health and wellbeing in the workplace by developing, implementing and evaluating an intervention targeting both clinical (depressive, anxiety disorders) and non-clinical (stress, burnout, depressive symptoms)…

A prospective observational cohort study to investigate predictors for comorbid insomnia in obstructive sleep apnea (COMISA)

To identify characteristics of comorbid insomnia in patients with OSA as a factor for predicting CPAP compliance. To answer this, the aim can be divided into three parts with corresponding research questions. Part 1: Identification of COMISA…

[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer

Primary objective:1. To evaluate the safety and tolerability of the [18F]fluoro-PEG-folate PET tracer2. To determine the pharmacokinetics (protein binding, biodistribution, clearance rate) of the [18F]fluoro-PEG-folate PET tracerSecondary objectives…

ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Primary objective:- To determine if TTFields at 200 kHz to the abdomen and pelvis with weekly paclitaxel in the treatment of recurrent ovarian cancer patients prolongs the overall survival of patients, compared to weekly paclitaxel treatment alone.…

Validation of mutation analysis in circulating tumor DNA with a ddPCR assay as diagnostic and follow-up tool for patients with a KIT exon 11 mutated GIST: GALLOP-11

To establish the negative predictive value of the designed KIT exon 11 circulating tumor mutation assay in relation to CT-scans (and/or MRI scans).

Determination of insulin-stimulated hepatic glucose uptake by PET-CT measurements

Primary objective:1. To determine the association between insulin-stimulated hepatic glucose uptake rate measured by dynamic [18F]-FDG PET and hepatic fat content in overweight/obese subjects. Exploratory objectives:1. To compare insulin-stimulated…

Optimizing machine settings for contrast-enhanced ultrasound imaging of uterine disorders

Optimize settings for contrast-enhanced ultrasound imaging of uterine disorders to obtain quantifiable images

Polarization Sensitive Optical coherence tomography-study

• In this pilot study, PS-OCT is used to image differences in fibrillary ocular structures associated with disease in patients with glaucoma, high myopia, exudative age-related macular degeneration with a suspicion of subretinal fibrosis and…

A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants with Familial Adenomatous Polyposis

The purpose of this study is to determine the effect of JNJ-64251330 in participants with Familial Adenomatous Polyposis(FAP) on colorectal polyp burden (sum of the polyp diameters).

A Phase 2, randomized, double-blind, placebo-controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib (SAR444671) in adult patients with moderate-to-severe atopic dermatitis who are inadequate responders or intolerant to topical corticosteroids

Primary objective:Assess the efficacy of rilzabrutinib in participants with atopic dermatitis (AD)Secondary objectives: * Assess the efficacy of rilzabrutinib at different time points* Assess the safety of rilzabrutinib

Targeting metabolic flexibility in ALS (MetFlex); safety and tolerability of trimetazidine for the treatment of ALS;An investigator initiated and conducted, multicentre, international, open-label Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND)

The objectives of this study are to determine:• The safety and tolerability of trimetazidine in patients with ALS/MND• The change from baseline in oxidative stress markers in patients with ALS/MND after the initiation of trimetazidine• The change…

A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy

The purpose of this Phase 3 study is to evaluate the safety and clinical efficacy of ligelizumab 240 mg and 120 mg given subcutaneously (s.c.) every 4 weeks (q4w) to ensure protection against allergic reaction by decreasing the sensitivity to oral…

An exploratory study investigating the effect of adding an appetite stimulant to an ONS on appetite-related outcomes in nursing home residents and in older adults in need of additional nutritional support

The main objective of this study is to explore the acute effects of adding an appetite stimulant to an ONS on the composite satiety score (CSS, a combined score of satiety, fullness, hunger and prospective food consumption) compared with an ONS…

ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Primary:To provide access to abrocitinib to adolescent and adult patients with or without background topical therapy who have inadequate treatment options due to inadequate response or intolerance to available approved medicated topical and systemic…

Dose response and safety of an oral PCSK9i, NNC0385-0434, in patients with established atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk on maximally tolerated statin dose and other lipid-lowering therapy requiring further LDL-C reduction

Primary objective:To demonstrate superiority of three dose levels of oral NNC0385-0434 versus placebo on percent change in LDL-C from baseline to week 12 in patients with established ASCVD or ASCVD risk on maximally tolerated statin dose and other…

COACH-pilot study, COgnition After intraCerebral Hemorrhage
Assessing cognitive function and related small vessel disease markers after intracerebral hemorrhage; a pilot study.

The overall aim of this pilot study is to investigate the development of MRI and CSF markers after CAA-related and HA-related ICH in relation to cognitive decline. The results from this pilot trial will be used to design a larger cohort study to…

Smart device for clinically validated MOVEment assessment and monitoring at home and in the clinic (SMOVE) PART 2: Algorithm validation in Parkinson patients

We here validate the algorithms for movement analysis that were developed previously in healthy participants (METc 2019.542; regarding quantitative aspects of movement) and that were derived from a review of the literature (regarding qualitative…

EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer.

The purpose of the study is to determine whether treatment with alpelisib in combination with olaparib can delay the time to cancer progression compared to standard-of-care chemotherapy in participants with your type of ovarian cancer known as…

A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia (SOLANO)

To assess the safety and tolerability of AZD8233 as compared with placebo in participants with hyperlipidaemia receiving maximally tolerated statin and/or ezetimibe therapy as defined by the investigator.

An exploratory, single-center, two-part study to describe mycosis fungoides characteristics and explore novel biomarkers with a multi-modal patient profiling approach by comparing MF patients to healthy volunteers

Primary- To evaluate disease-related characteristics and biomarkers in patients with mycosis fungoides compared to healthy volunteers; Secondary- To evaluate the variability of the selected biomarkers between patients and within patients over time…